Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 4—April 2011

Research

Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands

Judith Spijkerman, Elske J.M. van Gils, Reinier H. Veenhoven, Eelko Hak, F. Yzerman, Arie van der Ende, Alienke J. Wijmenga-Monsuur, Germie P.J.M. van den Dobbelsteen, and Elisabeth A.M. SandersComments to Author 
Author affiliations: Author affiliations: University Medical Center, Utrecht, the Netherlands (J. Spijkerman, E.J.M. van Gils, E.A.M. Sanders); Spaarne Hospital, Hoofddorp, the Netherlands (J. Spijkerman, E.J.M. van Gils, R.H. Veenhoven); University Medical Center, Groningen, the Netherlands (E. Hak); Regional Laboratory of Public Health, Haarlem, the Netherlands (E.P.F. Yzerman); Academic Medical Center, Amsterdam, the Netherlands (A. van der Ende); Netherlands Vaccine Institute, Bilthoven, the Netherlands (A.J. Wijmenga-Monsuur, G.P.J.M. van den Dobbelsteen)

Main Article

Table 2

Frequencies of nasopharyngeal carriage of Streptococcus pneumoniae in children and their parents before and 3 years after implementation of PCV7 vaccination program, the Netherlands*

Participant s Pre-PCV7, no. (%) Post-PCV7, no. (%)† OR‡ (95% CI) aOR§ (95% CI)
11-mo-old children n = 319 n = 329
PCV7 122 (38) 25 (8) 0.13 (0.08–0.21) 0.14 (0.09–0.23)
Non-PCV7 92 (29) 129 (39) 1.59 (1.15–2.21) 1.64 (1.15–2.32)
All
214 (67)
154 (47)
0.43 (0.31–0.59)
0.44 (0.31–0.63)
24-mo-old children n = 321 n = 330
PCV7 114 (36) 14 (4) 0.08 (0.05–0.14) 0.08 (0.05–0.15)
Non-PCV7 97 (30) 148 (45) 1.88 (1.36–2.59) 2.01 (1.43–2.84)
All
211 (66)
162 (49)
0.50 (0.37–0.69)
0.51 (0.36–0.72)
Parents n = 296 n = 324
PCV7 25 (8) 2 (1) 0.07 (0.02–0.29) 0.06 (0.01–0.26)
Non-PCV7 25 (8) 49 (15) 1.93 (1.16–3.22) 1.98 (1.16–3.37)
All 50 (17) 51 (16) 0.92 (0.60–1.41) 0.90 (0.57–1.40)

*PCV7, all serotypes included in 7-valent pneumococcal conjugate vaccine; OR, odds ratio; CI, confidence interval; aOR; adjusted odds ratio; non-PCV7, all other serotypes not included in 7-valent pneumococcal conjugate vaccine; all; all pneumococcal serotypes.
†325/329 (99%) swabs are taken just before the booster vaccination at 11 mo of age and 4/329 (1%) children had received a booster vaccination within 1 week before the sample was obtained.
‡All ORs are based on comparison with pre-PCV7 control cohort.
§For children, ORs were adjusted by multivariate analysis for sex, month of sampling, presence of siblings in the household, day care attendance, passive smoke exposure indoors, symptoms of a respiratory tract infection during sampling, and antimicrobial drug use within 1 mo before the sample was taken. For parents, ORs were adjusted for sex, months of sampling, antimicrobial drug use within 1 month before the sample was taken, and active smoking.

Main Article

TOP